Follow
Marcell Csanádi
Marcell Csanádi
Health economist, Syreon Research Institute
Verified email at syreon.eu - Homepage
Title
Cited by
Cited by
Year
HTA implementation roadmap in Central and Eastern European countries
Z Kaló, A Gheorghe, M Huic, M Csanádi, FB Kristensen
Health economics 25, 179-192, 2016
942016
Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
A Inotai, CPJ Prins, M Csanadi, D Vitezic, C Codreanu, Z Kalo
Expert opinion on biological therapy 17 (8), 915-926, 2017
662017
Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts
A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ...
BioMed research international 2018, 2018
392018
HTA implementation in Latin American countries: comparison of current and preferred status
D Rosselli, C Quirland-Lazo, M Csanádi, EMR de Castilla, NC González, ...
Value in health regional issues 14, 20-27, 2017
382017
All‐cause mortality versus cancer‐specific mortality as outcome in cancer screening trials: A review and modeling study
EAM Heijnsdijk, M Csanádi, A Gini, K Ten Haaf, R Bendes, A Anttila, ...
Cancer medicine 8 (13), 6127-6138, 2019
372019
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
P Ozieranski, M Csanadi, E Rickard, J Tchilingirian, S Mulinari
JAMA network open 2 (6), e196253-e196253, 2019
352019
When health technology assessment is confidential and experts have no power: the case of Hungary
M Csanádi, O Löblová, P Ozierański, A Harsányi, Z Kaló, M McKee, ...
Health Economics, Policy and Law 14 (2), 162-181, 2019
312019
Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence
G Lukács, Á Kovács, M Csanádi, M Moizs, I Repa, Z Kaló, Z Vokó, ...
Cancer Management and Research 11, 9849, 2019
272019
The emerging social science literature on health technology assessment: a narrative review
O Löblová, T Trayanov, M Csanádi, P Ozierański
Value in Health 23 (1), 3-9, 2020
242020
The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks
J Priaulx, E Turnbull, E Heijnsdijk, M Csanádi, C Senore, HJ de Koning, ...
Journal of health services research & policy 25 (1), 49-58, 2020
242020
Policy practices to maximise social benefit from biosimilars
A Inotai, M Csanádi, D Vitezic, I Francetic, T Tesar, T Bochenek, ...
J Bioequivalence Bioavailability 9 (4), 467-472, 2017
242017
A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease
M Csanadi, T Agh, A Tordai, T Webb, D Jeyakumaran, N Sengupta, ...
Expert review of hematology 12 (5), 311-323, 2019
232019
The implications of external price referencing on pharmaceutical list prices in Europe
M Csanádi, Z Kaló, CPJ Prins, E Grélinger, AM Kiss, FU Fricke, L Fuksa, ...
Health Policy and Technology 7 (3), 243-250, 2018
222018
Implementation of palliative care consult Service in Hungary–integration barriers and facilitators
AT Zemplényi, Á Csikós, M Csanádi, M Rutten-van Mölken, C Hernandez, ...
BMC Palliative Care 19 (1), 1-12, 2020
192020
Drug policy in Hungary
A Inotai, M Csanádi, A Harsányi, B Németh
Value in health regional issues 13, 16-22, 2017
192017
Overview on the current implementation of health technology assessment in the healthcare system in Hungary
B Németh, M Csanádi, Z Kaló
International journal of technology assessment in health care 33 (3), 333-338, 2017
192017
Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives
M Csanádi, A Inotai, O Oleshchuk, O Lebega, B Alexandra, O Piniazhko, ...
International Journal of Technology Assessment in Health Care, 1-8, 2019
182019
Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary
A Harsányi, M Csanádi, K Márky, ÁZ Vincziczki, Z Kaló, A Inotai
Expert review of pharmacoeconomics & outcomes research 20 (6), 653-659, 2020
172020
Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a …
JG Pitter, M Csanádi, A Szigeti, G Lukács, Á Kovács, M Moizs, I Repa, ...
BMC health services research 19 (1), 1-13, 2019
172019
Transparency in practice: Evidence from ‘verification analyses’ issued by the Polish Agency for Health Technology Assessment in 2012–2015
P Ozierański, O Löblová, N Nicholls, M Csanádi, Z Kaló, M McKee, L King
Health Economics, Policy and Law 14 (2), 182-204, 2019
172019
The system can't perform the operation now. Try again later.
Articles 1–20